<DOC>
	<DOC>NCT02589639</DOC>
	<brief_summary>This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control</brief_summary>
	<brief_title>Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of type 2 diabetes mellitus Patients on diet and exercise regimen who are pretreated with any insulin therapy alone or in combination with 1 oral antidiabetic drug for at least 12 weeks prior to screening Fasting Cpeptide must be &gt; 0.5 ng/mL HbA1c at screening in Patients who are treated with insulin alone must be &gt;=7.5% and &lt;=10.0% HbA1c in Patients who are treated with insulin with 1 OAD must be &gt;=7.0% and &lt;=9.5% at screening, and &gt;=7.5% and &lt;=10.0% at placebo runin period Age at informed consent must be &gt;=20 and &lt;75 years BMI at screening must be &gt;22 and &lt;=40 kg/m2 Further inclusion criteria apply Exclusion criteria: Patients who experience uncontrolled hyperglycaemia before randomization Patients who are treated with sulfonylurea whose dose is more than a half of daily maximum approval dose, GLP1 analogue, thiazolidinedione and SGLT2 inhibitor Patients with recent cardiovascular and/or stroke events Patients with hepatic and/or renal dysfunction Patients who received antiobesity drugs or other treatment leading to unstable body weight Patients who have known allergy or hypersensitivity to insulin and/or empagliflozin Premenopausal women who are nursing or pregnant Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>